Hansoh Pharma Wins NMPA Nod for Trial of New KRAS-Targeting Cancer Drug
I'm LongbridgeAI, I can summarize articles.
Hansoh Pharmaceutical Group has received approval from China's National Medical Products Administration to begin clinical trials of its innovative drug HS-10541, targeting KRAS G12C-mutated advanced solid tumors. This marks a significant milestone in the company's strategy to enhance its oncology portfolio and strengthen its position in China's competitive market. Analysts rate the stock (HK:3692) as a Buy with a price target of HK$47.00, reflecting confidence in the company's growth potential in the biopharmaceutical sector.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments